As we discussed above, CD300a deletion or CD300a neutralizing antibody attenuates inflammation and ameliorates neurological deficits during the superacute phase of ischemic stroke (Nakahashi-Oda et al., 2021). The gene discussed is CD300A; the disease is ischemic stroke.